Efficacy of trabectedin for the treatment of liposarcoma.

about

Myxoid liposarcoma: local relapse and metastatic pattern in 43 patients.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.

P2860

Q55306637-73D58ADD-2E04-4CA4-98E8-8585B00AC761 Q55365628-EE1AEAEB-001F-40B4-963E-1C0957A52A95

P2860

Efficacy of trabectedin for the treatment of liposarcoma.

Item

http://www.wikidata.org/entity/Q38951318

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Efficacy of trabectedin for the treatment of liposarcoma.

@en

type

Item

label

Efficacy of trabectedin for the treatment of liposarcoma.

@en

prefLabel

Efficacy of trabectedin for the treatment of liposarcoma.

@en

P1476

Efficacy of trabectedin for the treatment of liposarcoma.

@en

P2093

Ritika Zijoo

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.

Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.

Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).

P304

1953-1962

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2016.1229304

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Margaret von Mehren

P577

2016-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27615729

http://www.w3.org/2001/XMLSchema#string

Efficacy of trabectedin for the treatment of liposarcoma.

about

P2860

P2860

Efficacy of trabectedin for the treatment of liposarcoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698